openPR Logo
Press release

Lawsuit filed for Investors in shares of Mallinckrodt plc (NYSE: MNK)

08-05-2019 10:32 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Mallinckrodt plc (NYSE: MNK) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in Mallinckrodt plc (NYSE: MNK) shares over alleged securities laws violations.

An investor, who purchased shares of Mallinckrodt plc (NYSE: MNK), filed a lawsuit in the U.S. over alleged Securities Laws violations by Mallinckrodt plc.

Investors who purchased shares of Mallinckrodt plc (NYSE: MNK) have certain options and for certain investors are short and strict deadlines running. Deadline: September 24, 2019. NYSE: MNK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

UK based Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. Among other products, Mallinckrodt’s portfolio includes H.P. Acthar Gel (“Acthar”), an injectable drug for various indications, such as rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others. Between February 28, 2018 and July 16, 2019, Acthar was in a Phase 2B study designed to assess its efficacy and safety as an investigational treatment for amyotrophic lateral sclerosis (“ALS”).
On May 1, 2019, the Wall Street Journal published an article claiming that Questcor, acquired by Mallinckrodt in 2014, "defrauded government health-care plans by illegally marketing H.P. Acthar Gel." The Company purportedly resorted to bribing doctors and their staff members. To market this expensive drug, the Company allegedly offered everything from Starbucks gift cards to free Las Vegas trips, lavish dinners, sponsored happy hours and karaoke excursions.
Then, on July 16, 2019, post-market, Mallinckrodt announced that the Company was permanently discontinuing the PENNANT Trial, assessing Acthar’s safety and efficacy as an ALS treatment. Mallinckrodt stated that it decided “to halt the trial after careful consideration of a recent recommendation by the study’s independent Data and Safety Monitoring Board” (“DSMB”), which “was based on the specific concern for pneumonia, which occurred at a higher rate in the ALS patients receiving Acthar Gel compared to those on placebo” and that “the board also mentioned other adverse events specific to this patient population.”

The plaintiff claims that between February 28, 2018 and July 16, 2019, the Defendants made false and/or misleading statements and/or failed to disclose that Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS, that accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of Mallinckrodt plc (NYSE: MNK) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Mallinckrodt plc (NYSE: MNK) here

News-ID: 1818222 • Views: 337

More Releases from Shareholders Foundation

Investigation announced for Investors in Genworth Financial, Inc. (NYSE: GNW)
An investigation was announced concerning potential securities laws violations by Genworth Financial, Inc. in connection with certain financial statements. Investors who purchased shares of Genworth Financial, Inc. (NYSE: GNW), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Genworth Financial, Inc. (NYSE: GNW) concerning whether a
Investigation announced for Long-Term Investors in shares of Dropbox, Inc. (NASD …
An investigation was announced for investors in shares of Dropbox, Inc. (NASDAQ: DBX) concerning potential breaches of fiduciary duties by certain directors of Dropbox, Inc.. Investors who are current long term investors in Dropbox, Inc. (NASDAQ: DBX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: DBX stocks follows
Deadline in Lawsuit for Investors in shares of Trulieve Cannabis Corp. (OTC: TCN …
The Shareholders Foundation announced that a deadline is coming up on February 28, 2020 in the lawsuit filed for certain investors of Trulieve Cannabis Corp. (OTC: TCNN) over alleged securities laws violations by Trulieve Cannabis Corp. Investors who purchased shares of Trulieve Cannabis Corp. (OTC: TCNN) have certain options and there are strict and short deadlines running. Deadline: February 28, 2020. OTC: TCNN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Investigation announced for Investors in shares of Canaan Inc. (NASDAQ: CAN)
An investigation was announced concerning potential securities laws violations by Canaan Inc. in connection with certain financial statements. Investors who purchased shares of Canaan Inc. (NASDAQ: CAN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Canaan Inc. (NASDAQ: CAN regarding its business, its prospects and its operations were materially

All 5 Releases


More Releases for Mallinckrodt

Global Radiopharmaceuticals Market 2019 - Bracco Imaging, Bayer, Mallinckrodt, N …
This new report by Eon Market Research, titled “Global Radiopharmaceuticals Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Radiopharmaceuticals industry at a global as well as regional and country level. Key facts analyzed in this report include the Radiopharmaceuticals market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study of the competitive
Codeine Market Demand And Inventory Analysis: Francopia, Noramco, Weifa, Mallinc …
The Global Codeine Market Overview: The Global Codeine Market Research Report is depicted by the presence of various worldwide, provincial, and local vendors. The market is highly fragmented with each player is focusing on to gain a Codeine market share. Exceptional competition due to the presence of several international players, recurrent variations in government protocols and regulations, and rapid advancements in technology to drive innovation are the key factors that drive
Ioversol Market Size 2017-2022 Ultraject, Guerbet, Mallinckrodt Pharmaceuticals
Ioversol market research 2017 Global market study " Ioversol Market Size 2017-2022 " analyses the crucial factors of the Ioversol market based on present industry situations, market demands, business strategies adopted by Ioversol market players and their growth scenario. This report isolates the Ioversol market based on the key players, Type, Application and Regions. The Ioversol report provides the past, present and future Ioversol industry Size, trends and the forecast information
Global Codeine Phosphate Market 2017- Mallinckrodt, Francopia, Noramco, Macfaria …
Global Codeine Phosphate Market 2017, presents a professional and in-depth study on the current state of the Codeine Phosphate market globally, providing basic overview of Codeine Phosphate market including definitions, classifications, applications and industry chain structure. Historical data available in the report elaborates on the development of the Codeine Phosphate market on a global and regional level. The report compares this data with the current Codeine Phosphate state of the
Global Codeine Phosphate Market 2017- Noramco, Macfarian Smith, Francopia, Malli …
The main objective of the report titled Global Codeine Phosphate Market is to give a complete idea of the Codeine Phosphate market for the duration of 2017-2022. The Codeine Phosphate report focuses on market overview, market growth factors, market segmentation, regional analysis and competitive players involved in Codeine Phosphate market. Global Codeine Phosphate market report provides qualitative and quantitative knowledge about Codeine Phosphate industry. The Codeine Phosphate report also provides various
Global Oxycodone Hydrochloride Market-Siegfried, Temad, Purdue Pharma, Mallinckr …
Global Oxycodone Hydrochloride Market report 2017 is an in-depth research on the current situation of the Oxycodone Hydrochloride industry. The Scope of the Oxycodone Hydrochloride research report: The Global Oxycodone Hydrochloride Market primarily includes a basic overview of the Oxycodone Hydrochloride industry. It also includes Oxycodone Hydrochloride definitions, classifications and applications. It segments the market by applications, types, regions, competitive players and also analyzes Oxycodone Hydrochloride market size, business share and Oxycodone